Summary of findings table ‐ Daratumumab plus standard therapy vs usual care
Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher adverse events: infections (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
- Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple… 2024 · Cochrane Headline outcomes onlyRisk Ratio 1.52 [1.3, 1.78]3 studies · 1644 participantsModerate